Our data therefore reinforce the notion that KRAS mutations may positively modulate tumor immunogenicity, possibly through higher tumor mutational burden or enhanced immune infiltration, thereby increasing responsiveness to immune checkpoint blockade [24,28,29]. This evidence concerns the gene KRAS and neoplasm.